Strain ultrasonic elastography imaging features of locally advanced breast cancer: association with response to neoadjuvant chemotherapy and recurrence-free survival

Table 3 Univariable and multivariable cox proportional hazards analyses of variables associated with recurrence–free survival

Characteristic	Univariable Analysis		Multivariable Analysis
Characteristic	Hazard Ratio	P Value	Hazard Ratio	P Value
Age (y)	0.987 (0.948, 1.028)	0.54
Tumor diameter (mm)	1.021 (0.996, 1.047)	0.102
Menopausal status		0.539
Premenopausal	0.747 (0.295, 1.894)
Postmenmopausal	Ref
Clinical T stage		0.001		0.005
T1 ~ 3	Ref		Ref
T4	5.668 (2.126, 15.110)		4.165 (1.532, 11.324)
Clinical N stage		0.02
N0 ~ 2	Ref
N3	3.207 (1.200, 8.569)
ER status		0.75
ER negative	0.846 (0.301, 2.373)
ER positive	Ref
PR status		0.57
PR negative	1.433 (0.415, 4.955)
PR positive	Ref
HER2 status		0.366
HER2 negative	0.636 (0.239, 1.695)
HER2 positive	Ref
Ki-67 index		0.738
≥30	1.236 (0.357, 4.274)
<30	Ref
Molecular subtype		0.603
Luminal type	Ref
Triple negative and HER2-enriched	1.478 (0.340, 6.249)
BMI		0.553
<25%	Ref
≥25%	1.333 (0.516, 3.444)
SE parameters before NAC
ES	1.065 (0.511, 2.217)	0.867
SR	1.138 (1.077, 1.202)	<0.001	1.114 (1.042, 1.191)	0.002
HP	8.508 (0.953, 75.99)	0.055
AR	1.086 (1.052, 1.120)	<0.001	1.064 (1.032, 1.097)	<0.001

ER Estrogen receptor, PR Progesterone receptor, HER2 Human epidermal growth factor receptor 2, Luminal A-like (ER-positive and/or PR-positive, HER2-negative, and Ki-67 expression < 14%), Luminal B-like/HER2-positive (ER-positive and/or PR-positive; HER2-positive and Ki-67 expression ⩾ 14%), Luminal B-like/HER2-negative (ER-positive and/or PR-positive; HER2-negative and Ki-67 expression ⩾ 14%), HER2-enriched (ER and PR-negative, and HER2-positive), and Triple-negative (ER-negative, PR-negative, and HER2-negative). BMI Body mass index, NAC Neoadjuvant chemotherapy, SE Strain elastography, ES Elasticity score, SR Strain ratio, HP Hardness percentage, AR Area ratio

ISSN: 1471-2342